Literature DB >> 29369473

Comparative pharmacology and toxicology of tramadol and tapentadol.

J Faria1,2,3, J Barbosa1,2,3, R Moreira1, O Queirós1, F Carvalho2, R J Dinis-Oliveira1,2,3.   

Abstract

Moderate-to-severe pain represents a heavy burden in patients' quality of life, and ultimately in the society and in healthcare costs. The aim of this review was to summarize data on tramadol and tapentadol adverse effects, toxicity, potential advantages and limitations according to the context of clinical use. We compared data on the pharmacological and toxicological profiles of tramadol and tapentadol, after an extensive literature search in the US National Library of Medicine (PubMed). Tramadol is a prodrug that acts through noradrenaline and serotonin reuptake inhibition, with a weak opioid component added by its metabolite O-desmethyltramadol. Tapentadol does not require metabolic activation and acts mainly through noradrenaline reuptake inhibition and has a strong opioid activity. Such features confer tapentadol potential advantages, namely lower serotonergic, dependence and abuse potential, more linear pharmacokinetics, greater gastrointestinal tolerability and applicability in the treatment of chronic and neuropathic pain. Although more studies are needed to provide clear guidance on the opioid of choice, tapentadol shows some advantages, as it does not require CYP450 system activation and has minimal serotonergic effects. In addition, it leads to less side effects and lower abuse liability. However, in vivo and in vitro studies have shown that tramadol and tapentadol cause similar toxicological damage. In this context, it is important to underline that the choice of opioid should be individually balanced and a tailored decision, based on previous experience and on the patient's profile, type of pain and context of treatment. SIGNIFICANCE: This review underlines the need for a careful prescription of tramadol and tapentadol. Although both are widely prescribed synthetic opioid analgesics, their toxic effects and potential dependence are not completely understood yet. In particular, concerning tapentadol, further research is needed to better assess its toxic effects.
© 2018 European Pain Federation - EFIC®.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29369473     DOI: 10.1002/ejp.1196

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  16 in total

1.  Neuropathic Pain in Pediatric Oncology: A Clinical Decision Algorithm.

Authors:  Doralina L Anghelescu; Jessica Michala Tesney
Journal:  Paediatr Drugs       Date:  2019-04       Impact factor: 3.022

2.  Individual short-acting opioids and the risk of opioid-related adverse events in adolescents.

Authors:  Cecilia P Chung; Stephen Todd Callahan; William O Cooper; William D Dupont; Katherine T Murray; Andrew D Franklin; Kathi Hall; Judith A Dudley; Charles Michael Stein; Wayne A Ray
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-16       Impact factor: 2.890

3.  Effects of CYP2C19 variants on the metabolism of tapentadol in vitro.

Authors:  Ren-Ai Xu; Ping Fang; Zhize Ye; Mingming Han; Jian-Ping Cai; Guo-Xin Hu
Journal:  Iran J Basic Med Sci       Date:  2022-05       Impact factor: 2.532

4.  The Effect of Orexin-2 and Endocannabinoid-1 Antagonists on Neuronal Activity of Hippocampal CA1 Pyramidal Neurons in Response to Tramadol in Rats.

Authors:  Vajihe Imanpour; Parham Reisi
Journal:  Adv Biomed Res       Date:  2022-03-30

Review 5.  Perioperative Pain Management and Opioid Stewardship: A Practical Guide.

Authors:  Sara J Hyland; Kara K Brockhaus; William R Vincent; Nicole Z Spence; Michelle M Lucki; Michael J Howkins; Robert K Cleary
Journal:  Healthcare (Basel)       Date:  2021-03-16

Review 6.  Tapentadol: an overview of the safety profile.

Authors:  Enrico Polati; Pier Luigi Canonico; Vittorio Schweiger; Massimo Collino
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

Review 7.  Tapentadol in the treatment of osteoarthritis: pharmacological rationale and clinical evidence.

Authors:  Giuseppe Rinonapoli; Stefano Coaccioli; Lorenzo Panella
Journal:  J Pain Res       Date:  2019-05-16       Impact factor: 3.133

8.  Evaluation of Abuse and Route of Administration of Extended-Release Tapentadol Among Treatment-Seeking Individuals, as Captured by the Addiction Severity Index-Multimedia Version (ASI-MV).

Authors:  Suzanne K Vosburg; Jared Beaumont; S Taryn Dailey-Govoni; Stephen F Butler; Jody L Green
Journal:  Pain Med       Date:  2020-09-01       Impact factor: 3.750

9.  Do gabapentin or pregabalin directly modulate the µ receptor?

Authors:  Preeti Manandhar; Bridin Patricia Murnion; Natasha L Grimsey; Mark Connor; Marina Santiago
Journal:  PeerJ       Date:  2021-04-12       Impact factor: 2.984

10.  Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling.

Authors:  Hyeon-Cheol Jeong; Soo Hyeon Bae; Jung-Woo Bae; Sooyeun Lee; Anhye Kim; Yoojeong Jang; Kwang-Hee Shin
Journal:  Pharmaceutics       Date:  2019-11-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.